Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 15 (6), 659-65

Niacin Therapy in Atherosclerosis

Affiliations
Review

Niacin Therapy in Atherosclerosis

C Daniel Meyers et al. Curr Opin Lipidol.

Abstract

Purpose of review: Well designed, randomized, placebo-controlled studies show that niacin prevents cardiovascular disease and death. Unfortunately, early studies and anecdotal evidence have limited its use by promoting the opinion that niacin is intolerable and contraindicated in diabetes. As evidence mounts that treating multiple lipid risk factors decreases cardiovascular risk, the use of niacin in the treatment of atherosclerosis is experiencing somewhat of a renaissance.

Recent findings: Emerging clinical evidence shows that niacin is both safe and effective in diabetes. Niacin beneficially alters lipoprotein subclass distribution and when used in combination with statins, has additional effects on lipoproteins. Niacin selectively and directly inhibits hepatic diacylglycerol acyltransferase 2, but not diacylglycerol acyltransferase 1, thus inhibiting hepatic triglyceride synthesis and very low density lipoprotein secretion. The recent discovery and characterization of a membrane-bound nicotinic acid receptor (HM74) explains niacin's acute inhibition of adipocyte lipolysis, but the role of HM74 in lowering triglycerides is unclear. Niacin possesses antioxidant, antiinflammatory, and other beneficial effects on atherosclerosis unrelated to lipid lowering. Finally, niacin appears to activate nuclear transcription factors such peroxisome proliferator activator receptor gamma, possibly via prostaglandin metabolism.

Summary: New data indicate that niacin alters lipoprotein metabolism in novel ways, and mediates other beneficial nonlipid changes that may be atheroprotective. This information forms the rationale for the use of niacin in combination with agents possessing complementary mechanisms of action (e.g. statins) for cardiovascular risk reduction beyond that observed with monotherapy. Further research into the specific mechanisms of niacin may identify additional targets for future drug development.

Similar articles

  • Nicotinic Acid (Niacin) Receptor Agonists: Will They Be Useful Therapeutic Agents?
    VS Kamanna et al. Am J Cardiol 100 (11 A), S53-61. PMID 18047854. - Review
    Nicotinic acid (niacin) favorably affects very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and lipoprotein (a) (LP[a]) and increases high-density lipop …
  • Recent Advances in Niacin and Lipid Metabolism
    VS Kamanna et al. Curr Opin Lipidol 24 (3), 239-45. PMID 23619367. - Review
    Recent advances have provided physiological mechanisms of action of niacin on lipid metabolism and atherosclerosis. Better understanding of niacin's actions on multiple t …
  • The Benefits of Niacin in Atherosclerosis
    S Tavintharan et al. Curr Atheroscler Rep 3 (1), 74-82. PMID 11123852. - Review
    Niacin favorably alters all major lipid subfractions at pharmacologic doses. Alone or in combination, it promotes regression of coronary artery disease, decreases coronar …
  • Mechanism of Action of Niacin
    VS Kamanna et al. Am J Cardiol 101 (8A), 20B-26B. PMID 18375237. - Review
    Nicotinic acid (niacin) has long been used for the treatment of lipid disorders and cardiovascular disease. Niacin favorably affects apolipoprotein (apo) B-containing lip …
  • Targeting Low HDL-cholesterol to Decrease Residual Cardiovascular Risk in the Managed Care Setting
    MJ Cziraky et al. J Manag Care Pharm 14 (8 Suppl), S3-28; quiz S30-1. PMID 19891279. - Review
    Statins are highly effective for lowering LDL-C levels and, consequently, cardiovascular event rates. However, statins do not eliminate cardiovascular risk. Even in the p …
See all similar articles

Cited by 33 PubMed Central articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback